Prior irinotecan hypersensitivity or toxicity that would suggest an inability to tolerate irinotecan 180 mg/m2 every 2 weeksXx_NEWLINE_xXPatient has a history of non-compliance to medical regimen or inability to grant consentXx_NEWLINE_xXInability to comply with dietary restrictions for foods, supplements, and medications with potential for adverse interactions with phenelzine or to otherwise cooperate fully with the investigator and study personnelXx_NEWLINE_xXInability to cooperate with treatment protocolXx_NEWLINE_xXInability or unwillingness of research participant or legal guardian to consentXx_NEWLINE_xXInability or unwillingness of research participant or legal guardian to consentXx_NEWLINE_xXInability to take oral medicationsXx_NEWLINE_xXInability to comply with protocol-mandated hospitalization and activities restrictionsXx_NEWLINE_xXInability to comply with requirements for cisplatin administration anti-emetic regimens post-treatmentXx_NEWLINE_xXHistory of non-compliance to medical regimen or inability to grant consentXx_NEWLINE_xXUnwillingness or inability to comply with procedures required in this protocolXx_NEWLINE_xXSignificantly altered mental status that would limit the understanding or rendering of informed consent and compliance with the requirements of this protocol. Unwillingness or inability to comply with the study protocol for any reason.Xx_NEWLINE_xXInability to comply with study and follow up procedureXx_NEWLINE_xXInability to comply with study and follow up procedureXx_NEWLINE_xXInability to lie flat and still for treatment delivery despite anti-anxiety and/or pain medicationsXx_NEWLINE_xXAny perceived inability to directly (and without the means of a legal guardian) provide informed consentXx_NEWLINE_xXAny medical or physical contraindication, or other inability to undergo hematopoietic progenitor cell (HPC) collectionXx_NEWLINE_xXSignificantly altered mental status that would limit the understanding or rendering of informed consent and compliance with the requirements of this protocol. Unwillingness or inability to comply with the study protocol for any reason.Xx_NEWLINE_xXInability to receive HCT due to alloimmunization, defined as the inability to receive packed red blood cell (pRBC) transfusion therapy.Xx_NEWLINE_xXInability to cooperate with treatment protocolXx_NEWLINE_xXPatient has a history of non-compliance to medical regimen or inability to grant consentXx_NEWLINE_xXInability to complete baseline QOL formsXx_NEWLINE_xXFailure of, inability to, or refusal to receive standard of care.Xx_NEWLINE_xXInability to swallow medicationsXx_NEWLINE_xXPatient has a history of non-compliance to medical regimen or inability to grant consentXx_NEWLINE_xXPatient has a history of non-compliance to medical regimen or inability to grant consentXx_NEWLINE_xXInability or unwillingness of legal guardian/representative to give written informed consentXx_NEWLINE_xXInability to start the protocol treatment within 1 month after study enrollmentXx_NEWLINE_xXSignificantly altered mental status that would limit the understanding or rendering of informed consent and compliance with the requirements of this protocol. Unwillingness or inability to comply with the study protocol for any reason.Xx_NEWLINE_xXPatient with inability to follow up.Xx_NEWLINE_xXInability to tolerate CPI therapy {if already starteXx_NEWLINE_xXThe patient has an inability or unwillingness to abide by the study protocol or cooperate fully with the Investigator or designee.Xx_NEWLINE_xXInability to undergo venipuncture and/or tolerate venous accessXx_NEWLINE_xXUnwillingness or inability to comply with study proceduresXx_NEWLINE_xXDONOR: Inability to achieve adequate venous accessXx_NEWLINE_xXInability to tolerate oral medications.Xx_NEWLINE_xXInability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment.Xx_NEWLINE_xXPatient inability to complete baseline screening 3-day diet recordXx_NEWLINE_xXInability to take oral medicationsXx_NEWLINE_xXInability or unwillingness (including psychological, familial, sociological, or geographical conditions) to comply with study and/or follow-up procedures as outlined in the protocol.Xx_NEWLINE_xXInability to swallow or absorb drugXx_NEWLINE_xXUnwillingness to participate or inability to comply with the protocol for the duration of the studyXx_NEWLINE_xXInability or unwillingness of research participant or legal guardian/representative to give written informed consentXx_NEWLINE_xXUnwillingness or inability to comply with study and follow-up proceduresXx_NEWLINE_xXInability or unwillingness or research participant or legal guardian/representative to give written informed consentXx_NEWLINE_xXUncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as judged by the investigator; or unwillingness or inability to follow the procedures required in the protocolXx_NEWLINE_xXPatients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consentXx_NEWLINE_xXInability or unwillingness to give informed consentXx_NEWLINE_xXInability to perform phone call and clinical follow-up at MD Anderson Cancer Center (MDACC)Xx_NEWLINE_xXInability to take ixazomib or abataceptXx_NEWLINE_xXRapidly progressive disease which, in the opinion of the investigator, may predispose to inability to tolerate treatment or trial proceduresXx_NEWLINE_xXInability to comply with the protocol and/or not willing or not available for followup assessmentsXx_NEWLINE_xXUnwillingness or inability to follow the procedures required in the protocol.Xx_NEWLINE_xXInability to swallow medicationsXx_NEWLINE_xXInability to tolerate premedication with dexamethasoneXx_NEWLINE_xXInability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.Xx_NEWLINE_xXInability to tolerate prolonged trendelenburg position as deemed by anesthesiologyXx_NEWLINE_xXInability or unwillingness to swallow oral medicationsXx_NEWLINE_xXInability to adhere to study and/or follow-up proceduresXx_NEWLINE_xXUncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as judged by the investigator; or unwillingness or inability to follow the procedures required in the protocolXx_NEWLINE_xXThe inability to participate/complete phase 1 care due to:Xx_NEWLINE_xXInability to comply with treatment per investigator discretionXx_NEWLINE_xXInability to follow standard of care follow up recommendations per investigator discretionXx_NEWLINE_xXInability to understand the informed consent document, to give consent voluntarily or to complete the study tasks, especially inability to understand and fulfill the health-related QOL questionnaire;Xx_NEWLINE_xXInability to attend scheduled clinic visitsXx_NEWLINE_xXInability to perform PFTsXx_NEWLINE_xXUnwillingness or inability to follow the procedures required in the protocol.Xx_NEWLINE_xXInability or unwillingness to swallowXx_NEWLINE_xXInability to lie still for the entire imaging time (due to cough, severe arthritis, etc.)Xx_NEWLINE_xXInability to tolerate intensive chemotherapy (e.g., patients with AML with 20%-30% blasts and TRM ?4).Xx_NEWLINE_xXInability to tolerate prophylactic anti-thrombotic therapyXx_NEWLINE_xXInability to tolerate at least one modality of diagnostic anatomic imaging, such as CT or MRIXx_NEWLINE_xXInability to comply with treatment per investigator discretionXx_NEWLINE_xXInability to complete neurocognitive assessments per investigator discretionXx_NEWLINE_xXUnwillingness or inability to follow the procedures required in the protocolXx_NEWLINE_xXPerceived inability to tolerate diagnostic or therapeutic proceduresXx_NEWLINE_xXInability to understand or give an informed consentXx_NEWLINE_xXNoncompliance - inability or unwillingness to comply with medical recommendations regarding therapy or follow-up, including smoking tobaccoXx_NEWLINE_xXInability or unwillingness of research participant or legal guardian/representative to give written informed consentXx_NEWLINE_xXCRITERIA FOR SCREENING: Medical, psychological, familial, sociological, or geographical condition that does not permit compliance with the protocol as judged by the PI or designee, or unwillingness or inability to follow protocol proceduresXx_NEWLINE_xXInvestigator's opinion of subject's probable noncompliance or inability to understand the trial and/or give adequate informed consent;Xx_NEWLINE_xXInability to undergo PET-CTXx_NEWLINE_xXInability to tolerate cyclophosphamide or undergo total body irradiation at the doses specified in the treatment planXx_NEWLINE_xXInability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medicationsXx_NEWLINE_xXInability to tolerate thromboprophylaxis (Cohorts B, C, E, F)Xx_NEWLINE_xXinability to take oral medicationXx_NEWLINE_xXinability to take oral medication;Xx_NEWLINE_xXHistory of non-compliance to medical regimen or inability to grant consentXx_NEWLINE_xXUnwillingness or inability to comply with procedures required in this protocolXx_NEWLINE_xXInability to be venipunctured and/or tolerate venous accessXx_NEWLINE_xXHistory of non-adherence to medical regimens or inability to grant consentXx_NEWLINE_xXInability to comply with medical therapy or follow-upXx_NEWLINE_xXPatients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consentXx_NEWLINE_xXUnwillingness or inability to comply with procedures required in this protocolXx_NEWLINE_xXInability to tolerate oral medicationXx_NEWLINE_xXInability to give informed consentXx_NEWLINE_xXInability to interrupt use of non-steroidal anti-inflammatory drugs (NSAIDS)Xx_NEWLINE_xXInability to co-operate with the requirements of the protocolXx_NEWLINE_xXInability or unwillingness of research participant or legal guardian/representative to give written informed consentXx_NEWLINE_xXInability to tolerate anesthesiaXx_NEWLINE_xXUnwillingness or inability to comply with study and follow-up proceduresXx_NEWLINE_xXanticoagulation with inability to stop anticoagulants prior to surgeryXx_NEWLINE_xXInability to lie flat on a treatment table for > 60 minutesXx_NEWLINE_xXInability or unwilling to swallow study drugXx_NEWLINE_xXInability to undergo brain MRI due to medical or personal reasons.Xx_NEWLINE_xXUnwillingness or inability to comply with study and follow-up proceduresXx_NEWLINE_xXInability to safely delay surgery by 8 weeks as per surgeon’s discretionXx_NEWLINE_xXUnwilling or inability to give informed consentXx_NEWLINE_xXInability to obtain informed consent from patient or surrogateXx_NEWLINE_xXInability to give informed consent and comply with the protocol.Xx_NEWLINE_xXInability to cooperate with the requirements of the protocolXx_NEWLINE_xXInability to undergo contrast radiological assessmentsXx_NEWLINE_xXInability to take or tolerate enteral medicationsXx_NEWLINE_xXInability to undergo magnetic resonance imagingXx_NEWLINE_xXInability to understand or give an informed consentXx_NEWLINE_xXSubjects unable to receive study treatment planning secondary to body habitus or inability to lie flat on the stomach for at least 1 hourXx_NEWLINE_xXSubjects unable to receive study treatment planning secondary to body habitus or inability to lie flat on the stomach at lengthXx_NEWLINE_xXInability to swallow medicationXx_NEWLINE_xXInability to comply with medical therapy or follow-upXx_NEWLINE_xXInability or unwillingness to comply with study procedures and protocolXx_NEWLINE_xXInability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatmentXx_NEWLINE_xXInability to swallow medicationsXx_NEWLINE_xXInability to complete the survey instrumentation accuratelyXx_NEWLINE_xXInability to undergo MRI due to personal or medical reasonsXx_NEWLINE_xXInability to undergo MRI due to personal or medical reasons (Arm B)Xx_NEWLINE_xXInability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medicationsXx_NEWLINE_xXNo unwillingness or inability to follow protocol requirementsXx_NEWLINE_xXInability to consentXx_NEWLINE_xXUnwillingness or inability to follow the procedures required in the protocolXx_NEWLINE_xXInability to give informed consent or lacks decision making capacityXx_NEWLINE_xXInability to provide consentXx_NEWLINE_xXUnwillingness or inability to comply with the study protocol for any other reasonXx_NEWLINE_xXPatient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consentXx_NEWLINE_xXInability or unwillingness to comply with, or follow study proceduresXx_NEWLINE_xXInability to adhere to study and/or follow-up proceduresXx_NEWLINE_xXUnwillingness or inability to comply with the study protocol for any other reasonXx_NEWLINE_xXInability to comply with medical therapy or follow-upXx_NEWLINE_xXAnergic, defined by the inability to make a Delayed-type Hypersensitivity (DTH) to at least one of the following: candida, mumps, tetanus or trichophyton (based upon availability)Xx_NEWLINE_xXInability to participate in study activities due to physical or mental limitationsXx_NEWLINE_xXInability or unwillingness to return for all the required follow-up visitsXx_NEWLINE_xXInability to deliver target dose with CyberKnife due to inability to image fiducialsXx_NEWLINE_xXInability to deliver target dose with CyberKnife due to normal tissue dose constraintsXx_NEWLINE_xXPatients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consentXx_NEWLINE_xXInability to participate in study activities due to physical or mental limitationsXx_NEWLINE_xXInability or unwillingness to return for all the required follow-up visitsXx_NEWLINE_xXInability to tolerate contrast dye for baseline CT imagingXx_NEWLINE_xXInability or unwillingness of research participant or legal guardian/representative to give written informed consentXx_NEWLINE_xXInability to comply with protocol requirements, including pharmacokinetic (PK) studies (phase I only) and genetic studiesXx_NEWLINE_xXUnwillingness or inability to comply with the study protocol for any reasonXx_NEWLINE_xXInability to tolerate PET and/or MRIXx_NEWLINE_xXInability to lie flat for > 1 hourXx_NEWLINE_xXCOHORTS 1 AND 2: HEALTHY VOLUNTEERS: Inability to comply with the requirements of the protocolXx_NEWLINE_xXSevere alloimmunization with inability to guarantee a supply of adequate PRBC donorsXx_NEWLINE_xXInability to grant informed consentXx_NEWLINE_xXInability to adequately visualize anatomy to perform the diagnostic or therapeutic surgical approach transorallyXx_NEWLINE_xXInability to understand or give an informed consentXx_NEWLINE_xXInability to obtain informed consentXx_NEWLINE_xXInability to tolerate periodic audiologic testing or to understand a language with established scoring for word recognition testingXx_NEWLINE_xXInability to practice contraception with condoms as prescribed by the protocolXx_NEWLINE_xXSubjects who have other conditions which in the opinion of the investigator contraindicate the receipt of HSV1716 or indicate subject’s inability to follow protocol requirementsXx_NEWLINE_xXInability to co-operate with the requirements of the protocolXx_NEWLINE_xXInability to give informed consent or assentXx_NEWLINE_xXInability to obtain a suitable donorXx_NEWLINE_xXInability to find a suitable donor for the patientXx_NEWLINE_xXContraindication to SBRT (this includes the inability to cooperate with any aspect of SBRT: such as the inability to lie still and breathe reproducibly)Xx_NEWLINE_xXUnwillingness or inability to follow the procedures outlined in the protocolXx_NEWLINE_xXInability to fit inside scanner due to body size (girth)Xx_NEWLINE_xXPrevious inability to tolerate any dose of paclitaxel (i.e., the subject required a paclitaxel dose reduction or discontinuation).Xx_NEWLINE_xXInability to give informed consentXx_NEWLINE_xXAny gastrointestinal tract disease or other medical condition resulting in the inability to take oral medicationsXx_NEWLINE_xXUnwillingness or inability to given written informed consent.Xx_NEWLINE_xXHas inability to take oral medications and/or has clinical or radiological diagnosis of bowel obstruction.Xx_NEWLINE_xXInability or unwillingness to sign the informed consent form.Xx_NEWLINE_xXInability to continue taking ibrutinib for any reasonXx_NEWLINE_xXInability to stop anticoagulants/antiplatelet therapy peri-operativelyXx_NEWLINE_xXSignificant cardiac disease resulting in inability to tolerate IV fluid hydration for cisplatinXx_NEWLINE_xXInability to swallow intact tablets or inability to take pembrolizumab or cabozantinibXx_NEWLINE_xXInability or unwillingness to comply with study and/or follow-up requirementsXx_NEWLINE_xXUnwillingness to participate or inability to comply with the protocol for the duration of the studyXx_NEWLINE_xXInability to give consent or adhere to follow-up scheduleXx_NEWLINE_xXAn unwillingness or inability (including psychological, familial, sociological, or geographical conditions) to comply with trial and/or follow-up procedures as outlined in the protocolXx_NEWLINE_xXInability to undergo magnetic resonance (MR) imaging to assess disease statusXx_NEWLINE_xXInability to have fiducial markers placedXx_NEWLINE_xXInability or unwillingness to tolerate endocrine therapyXx_NEWLINE_xXInability to swallow medicationXx_NEWLINE_xXInability or unwillingness to have pleural catheter placedXx_NEWLINE_xXInability to take oral medications on a continuous basisXx_NEWLINE_xXInability to tolerate thromboprophylaxisXx_NEWLINE_xXInability to travel to the National Institutes of Health (NIH) Clinical CenterXx_NEWLINE_xXInability to tolerate venous accessXx_NEWLINE_xXInability to comply with study instructionsXx_NEWLINE_xXInability to test core biopsy for study markersXx_NEWLINE_xXInability to comply with protocolXx_NEWLINE_xXInability to undergo MRI evaluation for treatment planning and follow-upXx_NEWLINE_xXInability to home monitor blood pressureXx_NEWLINE_xXAny medical or physical contraindication or any other inability to undergo HSPC collectionXx_NEWLINE_xXPatient has a history of non-compliance to medical regimen or inability to grant consentXx_NEWLINE_xXPatient has a history of non-compliance to medical regimen or inability to grant consentXx_NEWLINE_xXPatient has a history of non-compliance to medical regimen or inability to grant consentXx_NEWLINE_xXPredicted inability to tolerate standard induction chemotherapy with daunorubicin and cytarabineXx_NEWLINE_xXAny medical or physical contraindication or other inability to undergo HSPC collectionXx_NEWLINE_xXPatient has a history of non-compliance to medical regimen or inability to grant consentXx_NEWLINE_xXContraindication to SBRT or TEMLA; this includes the inability to cooperate with any aspect of SBRT such as the inability to lie still and breathe reproduciblyXx_NEWLINE_xXInability to understand or give an informed consentXx_NEWLINE_xXSubject has an inability or unwillingness, in the opinion of the investigator, to comply with the protocol requirementsXx_NEWLINE_xXInability to take medications by mouthXx_NEWLINE_xXInability to inject medication or test for finger stick glucoseXx_NEWLINE_xXHigh risk of inability to comply with transplant protocol, or inability to give appropriate informed consent in the estimation of the principal investigator (PI), social work, psychiatry, or the stem cell transplant teamXx_NEWLINE_xXInability to obtain informed consent because of psychiatric or complicating medical problemsXx_NEWLINE_xXInability or unwillingness to return to required visits and follow-up examsXx_NEWLINE_xXInability to understand or give an informed consentXx_NEWLINE_xXInability to comply with the treatment protocol or to undergo pre-specified follow-up tests for safety or effectivenessXx_NEWLINE_xXPatient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consentXx_NEWLINE_xXUnwillingness to give written informed consent, unwillingness to participate, or inability to comply with the protocol for the duration of the studyXx_NEWLINE_xXUnwillingness or inability to comply with protocol.Xx_NEWLINE_xXInability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment.Xx_NEWLINE_xXUnwillingness or inability to comply with procedures required in this protocol.Xx_NEWLINE_xXInability to swallow or absorb orally-administered medication.Xx_NEWLINE_xXInability or unwillingness of research participant or legal guardian/representative to give written informed consentXx_NEWLINE_xXInability to tolerate transrectal ultrasound (TRUS).Xx_NEWLINE_xXInability to Participate Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.Xx_NEWLINE_xXInability to lie still for the entire imaging time (due to cough, severe arthritis, etc.)Xx_NEWLINE_xXInability to swallow oral medication or inability or unwillingness to comply with the administration requirements related to alisertibXx_NEWLINE_xXPatient has a history of non-compliance to medical regimen or inability to grant consentXx_NEWLINE_xXPatients with any significant history of non-adherence to medical regimens or with inability to grant reliable informed consentXx_NEWLINE_xXFor patient with LM, inability to undergo collection of CSFXx_NEWLINE_xXInability to receive a port or peripherally inserted central catheter (PICC) lineXx_NEWLINE_xXInability to assess BRAF or NRAS mutation status; hypersensitivity to digoxinXx_NEWLINE_xXInability to be venipunctured and/or tolerate venous accessXx_NEWLINE_xXInability to understand or give an informed consentXx_NEWLINE_xXHistory of non-compliance to medical regimens or inability to grant consentXx_NEWLINE_xXPatient has a history of non-compliance to medical regimen or inability to grant consentXx_NEWLINE_xXInability to take oral medicationXx_NEWLINE_xXHave a perceived inability to tolerate diagnostic or therapeutic procedures, particularly treatment in radiation isolationXx_NEWLINE_xXRapidly progressive disease which, in the opinion of the Investigator, may predispose to inability to tolerate treatment or trial proceduresXx_NEWLINE_xXInability or unwillingness of research participant or legal guardian/representative to give written informed consentXx_NEWLINE_xXPatients with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consentXx_NEWLINE_xXInability to tolerate thromboprophylaxisXx_NEWLINE_xXParticipants' inability to adhere to or tolerate protocol or study procedures.Xx_NEWLINE_xXPatient has a history of non-compliance to medical regimen or inability to grant consentXx_NEWLINE_xXInability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements or GI procedure that could interfere with the oral absorption or tolerance of treatmentXx_NEWLINE_xXUnwillingness or inability to comply with the protocolXx_NEWLINE_xXUnwillingness or inability to follow the procedures required in the protocolXx_NEWLINE_xXInability to tolerate PO dosingXx_NEWLINE_xXPatient has a history of non-compliance to medical regimen or inability to grant consentXx_NEWLINE_xXInability to comply with IL-2 treatment regimenXx_NEWLINE_xXParticipants with inability to comply with IL-2 treatment regimenXx_NEWLINE_xXPatient has a known history of non-compliance to medical regimen or inability to grant consentXx_NEWLINE_xXInability to undergo magnetic resonance imagingXx_NEWLINE_xXInability to swallow oral medication or inability or unwillingness to comply with the administration requirements related to alisertibXx_NEWLINE_xXInability to undergo MRIXx_NEWLINE_xXInability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment.Xx_NEWLINE_xXInability to co-operate with the requirements of the protocolXx_NEWLINE_xXInability to lie on the TomoTherapy treatment table for one hourXx_NEWLINE_xXUnwillingness or inability to comply with study and follow-up proceduresXx_NEWLINE_xXInability to participate in physical activity because of co-morbidity or disability (e.g., severe arthritic conditions)Xx_NEWLINE_xXInability to take oral medicationsXx_NEWLINE_xXInability to give informed consentXx_NEWLINE_xXUnwillingness to participate or inability to comply with the protocol for the duration of the studyXx_NEWLINE_xXUnwillingness or inability to provide written informed consent and comply with the study protocol for any reasonXx_NEWLINE_xXInability or unwillingness to comply with birth control requirements or regional REMS/RevAid programsXx_NEWLINE_xXInability to tolerate cyclophosphamide or undergo total body irradiation at the doses specified in the treatment planXx_NEWLINE_xXUnwillingness to give written informed consent, unwillingness to participate, or inability to comply with the protocol for the duration of the studyXx_NEWLINE_xXUncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as judged by the Investigator; or subject unwillingness or inability to follow the procedures required in the protocolXx_NEWLINE_xXInability or unwillingness of research participant or legal guardian/representative to give written informed consentXx_NEWLINE_xXInability or unwillingness of research participant or legal guardian/representative to give written informed consentXx_NEWLINE_xXInability to undergo MRI due to personal and medical reasonsXx_NEWLINE_xXInability or unwillingness to receive antithrombotic therapyXx_NEWLINE_xXInability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatmentXx_NEWLINE_xXUnwillingness or inability to receive conventional chemotherapyXx_NEWLINE_xXInability to swallow or absorb drugXx_NEWLINE_xXUnwillingness or inability to comply with the protocolXx_NEWLINE_xXUnwillingness to participate or inability to comply with the protocol for the duration of the studyXx_NEWLINE_xXInability or unwillingness to comply with study and/or follow-up procedures outlined in the protocolXx_NEWLINE_xXInability to avoid exposure of skin or eyes to direct sunlight or bright indoor light for at least 30 daysXx_NEWLINE_xXInability to obtain venous access in the antecubital region to administer PHO or sedation for endoscopy proceduresXx_NEWLINE_xXInability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatmentXx_NEWLINE_xXUnwillingness or inability to comply with protocol.Xx_NEWLINE_xXInability to understand or comply with study protocolXx_NEWLINE_xXInability to tolerate lying flat on treatment table for greater than 30 minutesXx_NEWLINE_xXInability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal condition that could interfere with the oral absorption or tolerance of treatment.Xx_NEWLINE_xXRefusal or inability to give informed consent to participate in the trialXx_NEWLINE_xXRegular use of thiazide diuretics (i.e., hydrochlorothiazide), which can lead to hypercalcemia, and unwillingness or inability to discontinue or switch to alternative anti-hypertensive agentXx_NEWLINE_xXSignificant malabsorption syndrome or inability to tolerate oral medicationsXx_NEWLINE_xXUnwillingness to participate or inability to comply with the protocol for the duration of the studyXx_NEWLINE_xXInability to lie prone or supine for one hourXx_NEWLINE_xXHistory of non-compliance to medical regimens or inability to grant consentXx_NEWLINE_xXInability or refusal to practice contraception during therapy (as physiologically relevant)Xx_NEWLINE_xXInability to give informed consentXx_NEWLINE_xXPerceived inability to tolerate diagnostic or therapeutic proceduresXx_NEWLINE_xXInability to understand or give an informed consentXx_NEWLINE_xXInability to take oral medicationXx_NEWLINE_xXInability to provide informed consent or to comply with the schedule of office and treatment visitsXx_NEWLINE_xXInability to give consentXx_NEWLINE_xXh. History of psychotropic drug abuse and inability to quitXx_NEWLINE_xXClinical conditions affecting the intake and use of oral medications (e.g., inability to swallow, chronic diarrhea, and intestinal obstruction)Xx_NEWLINE_xXIs unwilling to give written informed consent, unwillingness to participate, or inability to comply with the protocol for the duration of the studyXx_NEWLINE_xXInability to tolerate oral medications.Xx_NEWLINE_xXInability to comply with the protocol activitiesXx_NEWLINE_xXGastrointestinal tract disease or previous surgical procedures resulting in an inability to take oral/feeding tube suspension or enteral medication or a requirement for IV alimentationXx_NEWLINE_xXInability to collect adequate stem cellsXx_NEWLINE_xXinability to visualize the prostatic tissue adequately on transrectal ultrasound imaging;Xx_NEWLINE_xXinability to comply with the protocol activitiesXx_NEWLINE_xXPerceived inability to tolerate diagnostic or therapeutic procedures, particularly treatment in radiation isolationXx_NEWLINE_xXInability to understand or give an informed consentXx_NEWLINE_xXPatient must be able to tolerate the procedures required in this study including periodic blood sampling, study related assessments, and management at the treating institution for the duration of the study. Inability to comply with protocol or study procedures (for example, an inability to swallow tablets) will be an exclusion criterion.Xx_NEWLINE_xXDONOR: Inability to achieve adequate venous accessXx_NEWLINE_xXDONOR: Inability to achieve adequate venous accessXx_NEWLINE_xXInability or unwillingness to comply with the treatment protocol, follow-up, or research testsXx_NEWLINE_xXInability or unwillingness or research participant or legal guardian/representative to give written informed consentXx_NEWLINE_xXInability or unwillingness to take folic acid, vitamin B12 supplementation or corticosteroidsXx_NEWLINE_xXInability to lie supine in a full body cast for approximately 30 minutes, the anticipated duration of each treatment sessionXx_NEWLINE_xXInability to swallow oral medication or inability or unwillingness to comply with the administration requirements related to alisertibXx_NEWLINE_xXUnwillingness or inability to comply with study and follow-up proceduresXx_NEWLINE_xXInability to receive TBI.Xx_NEWLINE_xXNo social support or inability to attend study-related visitsXx_NEWLINE_xXHistory of non-compliance to medical regimens or inability to grant consentXx_NEWLINE_xXUnwillingness or inability to follow the procedures outlined in the protocol.Xx_NEWLINE_xXPhysical or psychiatric conditions that in the estimation of the investigator place the patient at high risk of toxicity, non-compliance, or inability to complete the study requirementsXx_NEWLINE_xXUnwillingness or inability to comply with the protocolXx_NEWLINE_xXMSC DONOR: inability to provide informed consentXx_NEWLINE_xXInability or unwillingness to take folic acid or vitamin B12 or dexamethasoneXx_NEWLINE_xXHigh risk of inability to comply with therapy in the estimation of the principal investigator (PI)Xx_NEWLINE_xXUnwillingness or inability to comply with the study protocol for any reason.Xx_NEWLINE_xXInability to swallow oral medications or any medical conditions that may affect intestinal absorption of the study agent or inability to comply with oral medicationXx_NEWLINE_xXInability to understand and inability to provide informed consentXx_NEWLINE_xXPatient has a history of non-compliance to medical regimen or inability to grant consent.Xx_NEWLINE_xXInability to take oral medications, due to impaired swallowing ability or poor absorption capacityXx_NEWLINE_xXUnwillingness to participate or inability to comply with the protocol for the duration of the studyXx_NEWLINE_xXInability to comply with study and follow up procedureXx_NEWLINE_xXInability to give an informed consentXx_NEWLINE_xXInability to comply with the study protocol.Xx_NEWLINE_xXInability or unwillingness or research participant or legal guardian/representative to give written informed consentXx_NEWLINE_xXActive alcohol abuse or other illness or circumstance that carries a likelihood of inability to comply with study treatment and follow-up or otherwise compromise the study’s objectivesXx_NEWLINE_xXInability to take oral medicationsXx_NEWLINE_xXUnwillingness or inability to comply with procedures required in this protocol.Xx_NEWLINE_xXInability to consent for the procedureXx_NEWLINE_xXInability to swallow food or any condition of the upper GI tract that precludes administration of oral medications.Xx_NEWLINE_xXInability to give informed consentXx_NEWLINE_xXLikely inability to comply with the protocol or cooperate fully with the investigator and site personnelXx_NEWLINE_xXUnwillingness or inability to follow the procedures outlined in the protocolXx_NEWLINE_xXInability to swallow or absorb drugXx_NEWLINE_xXInability to home monitor blood pressureXx_NEWLINE_xXUnwillingness or inability to comply with procedures required in this protocolXx_NEWLINE_xXUncontrolled medical conditions (e.g., diabetes mellitus, hypertension, liver disease or uncontrolled infection), psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol; or unwillingness or inability to follow the procedures required in the protocol.Xx_NEWLINE_xXInability to tolerate or absorb an oral medication due to any cause, including but not limited to malabsorption syndromesXx_NEWLINE_xXKnown or suspected inability to comply with the study protocol.Xx_NEWLINE_xXInability to undergo MRI evaluation for treatment planning and follow-upXx_NEWLINE_xXKnown or suspected inability to fully comply with study protocol.Xx_NEWLINE_xXGastrointestinal disease resulting in an inability to take oral medication or a requirement for intravenous hyperalimentation.Xx_NEWLINE_xXPatients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consentXx_NEWLINE_xXKnown or suspected inability to fully comply with study protocolXx_NEWLINE_xXUnwillingness or inability to follow the procedures required in the protocol.Xx_NEWLINE_xXInability to achieve or maintain a minimum mean arterial pressure (MAP) of 65mmHgXx_NEWLINE_xXInability to consent.Xx_NEWLINE_xXInability to give informed consentXx_NEWLINE_xXInability to comply with medical therapy or follow-upXx_NEWLINE_xXInability or unwillingness of research participant or legal guardian or representative to give written informed consentXx_NEWLINE_xXInability to stop intake of NSAIDS (non steroidal anti inflammatory drugs) for several daysXx_NEWLINE_xXInability or unwillingness of research participant or legal guardian/representative to give written informed consentXx_NEWLINE_xXInability to give informed consent because of psychiatric problems, or complicated medical problems.Xx_NEWLINE_xXPatient has a history of non-compliance to medical regimen or inability to grant consentXx_NEWLINE_xXInability to undergo SRS due to claustrophobiaXx_NEWLINE_xXFailure/inability/unwillingness to provide names and contact information for two family members or friends to serve as emergency contacts during the course of the studyXx_NEWLINE_xXCAREGIVERS: Inability to complete study questionnairesXx_NEWLINE_xXUnwillingness or inability to comply with mandated blood draws.Xx_NEWLINE_xXInability to lay supine for one hour at a time, given the nature of the massage interventionXx_NEWLINE_xXInability or unwillingness of individual to give written informed consentXx_NEWLINE_xXInability of the patient to provide informed consent (i.e. dementia, cognitive impairment, non-English speakers)Xx_NEWLINE_xXInability to comply with follow up visitsXx_NEWLINE_xXInability to complete the baseline assessment forms or to understand the recommendations for participation in the studyXx_NEWLINE_xXInability to exerciseXx_NEWLINE_xXPatient has inability to tolerate 4D CT scan (for example; contrast intravenous [IV] allergy, claustrophobia, renal disease)Xx_NEWLINE_xXHSCT CGs: Inability to complete role responsibilities 24 hours per day for at least 50% of time (>= 50 days)Xx_NEWLINE_xXInability to complete study formsXx_NEWLINE_xXCognitive impairment or inability to consent to treatment, as determined by the patient's oncologistXx_NEWLINE_xXInability to travel to the NIH, for example, due to physical limitations, for the in-person evaluation(s)Xx_NEWLINE_xXInability to cooperate with NIPPVXx_NEWLINE_xXInability to swallow study medicationXx_NEWLINE_xXInability to communicate in EnglishXx_NEWLINE_xXInability to complete pain self-reportXx_NEWLINE_xXInability to complete or perform measures of patient-reported outcomes or neurocognitive testing on the computerXx_NEWLINE_xXInability to access a computer with internet or inability to use a computer with internet provided by the study as indicated by self-reportXx_NEWLINE_xXSUPPORT PROVIDER: Inability to access a computer with internet or inability to use a computer with internet provided by the study as indicated by self-reportXx_NEWLINE_xXInability to tolerate preoperative oral intakeXx_NEWLINE_xXMental impairment leading to inability to cooperateXx_NEWLINE_xXInability to conceive after 6 months of unprotected intercourse with maleXx_NEWLINE_xXInability to tolerate a proton pump inhibitor (PPI)Xx_NEWLINE_xXInability or unwillingness to understand or cooperate with study proceduresXx_NEWLINE_xXMental impairment leading to inability to cooperateXx_NEWLINE_xXInability to complete the baseline assessment forms or to understand the recommendations for participation in the studyXx_NEWLINE_xXInability or unwillingness to follow study protocol.Xx_NEWLINE_xXSelf-reported inability to walk 2 blocks (at any pace)Xx_NEWLINE_xXInability to receive lumbar intrathecal injection because of other factorsXx_NEWLINE_xXInability to comply with the pre-op dietXx_NEWLINE_xXInability to increase food intake (e.g., esophageal obstruction, intractable nausea and vomiting)Xx_NEWLINE_xXUnwillingness or inability to cooperate, or, for the parents or guardians of minors, to give consent, or for the child to give assent, or any condition of sufficient severity to impair cooperation with the studyXx_NEWLINE_xXInability to assume or maintain a seated position for the procedureXx_NEWLINE_xXInability to tolerate oral or enteral medicationXx_NEWLINE_xXInability to taste or smell due to medication or health conditionXx_NEWLINE_xXInability to provide informed assent/permission/consentXx_NEWLINE_xXInability to complete the baseline assessment forms or to understand the recommendations for participation in the studyXx_NEWLINE_xXInability to comply with protocol requirements including refusal to forego pre-procedural opioid useXx_NEWLINE_xXInability to comply with study requirementXx_NEWLINE_xXInability to understand English as some study instruments have not been validated in other languagesXx_NEWLINE_xXInability to give informed consentXx_NEWLINE_xXInability to provide informed consent; potential participants will be identified by our collaborating physiciansXx_NEWLINE_xXInability to complete all study-related visitsXx_NEWLINE_xXInability or unwillingness of research participant or legal guardian/representative to give written informed consentXx_NEWLINE_xXAllergies or inability to tolerate beta blockers previously due to bradycardia, hypotension, or atrioventricular (AV) blockXx_NEWLINE_xXInability to take medications by mouthXx_NEWLINE_xXInability to tolerate imaging procedures in the opinion of the investigator or treating physicianXx_NEWLINE_xXInability to comply with IL-2 treatment regimenXx_NEWLINE_xXInability to get brain MRIXx_NEWLINE_xXInability to complete the baseline assessment forms or to understand the recommendations for participation in the studyXx_NEWLINE_xXInability or unwillingness to give informed consentXx_NEWLINE_xXInability to perform phone call and clinical follow-up at MD Anderson Cancer Center (MDACC)Xx_NEWLINE_xXInability to commit to local follow up for device managementXx_NEWLINE_xXHas inability to give informed consent or comply with study requirementsXx_NEWLINE_xXInability to comprehend written or spoken EnglishXx_NEWLINE_xXImmobility as defined by inability to ambulate unassistedXx_NEWLINE_xXInability to comply with follow up regimenXx_NEWLINE_xXInability to lay supine for one hour at a time, given the nature of the massage interventionXx_NEWLINE_xXInability or unwillingness of individual to give written informed consentXx_NEWLINE_xXInability or unwillingness to comply with skin care instructions and follow-upXx_NEWLINE_xXInability or unwillingness of research participant or legal guardian/representative to give written informed consentXx_NEWLINE_xXInability to undergo breast MRI (e.g. claustrophobia)Xx_NEWLINE_xXInability to tolerate sedated upper endoscopy due to cardiopulmonary instability or otherXx_NEWLINE_xXHave a known history of inability to absorb an oral agentXx_NEWLINE_xXKnown inability to participate in the ongoing appointments for the four months of the study and scheduled follow-up tests.Xx_NEWLINE_xXInability or unwillingness to cooperate with the study proceduresXx_NEWLINE_xXMental impairment leading to inability to cooperateXx_NEWLINE_xXInability or unwillingness to abstain from non-protocol use of aspirin or NSAIDs or to provide blood, urine, or stool samples or colon biopsies during the studyXx_NEWLINE_xXInability to perform exercise with dominant legXx_NEWLINE_xXUnwillingness or inability to participate or give informed consentXx_NEWLINE_xXKnown inability to participate in the scheduled follow-up testsXx_NEWLINE_xXInability to understand consent proceduresXx_NEWLINE_xXParticipants with known inability to adequately absorb oral medicationXx_NEWLINE_xXAny physical or mental limitation that would prevent participation in study activities (Including but not limited to grade 4 neuropathy or inability to ambulate)Xx_NEWLINE_xXKnown inability to participate in the ongoing appointments for the four months of the study and scheduled follow-up testsXx_NEWLINE_xXInability to come to Vanderbilt General Clinical Research Center (GCRC) for research proceduresXx_NEWLINE_xXInability to commit to the intervention scheduleXx_NEWLINE_xXInability to give informed consentXx_NEWLINE_xXSelf-reported inability to walk at least 2 blocks (at any pace).Xx_NEWLINE_xXInability to exercise due to musculoskeletal issue, osteoarthritis or underlying cardiac diseaseXx_NEWLINE_xXHave a known history of inability to absorb an oral agentXx_NEWLINE_xXInability to provide informed consent (and assent, if subject is under the age of 18)Xx_NEWLINE_xXInability to obtain a biopsy of the tumor as deemed by the study interventional radiologistXx_NEWLINE_xXInability to give informed consentXx_NEWLINE_xXInability to undergo anti-3-[18F]FACBC PET-CTXx_NEWLINE_xXInability or unwillingness of patient, parent, or guardian to consentXx_NEWLINE_xXInability to lie in the scanner for 30 minutesXx_NEWLINE_xXPatients not capable of undergoing a PET/MRI study due to weight, claustrophobia, or inability to lie still for the duration of the examXx_NEWLINE_xXPatients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the examXx_NEWLINE_xXInability to provide informed consent on their own behalfXx_NEWLINE_xXSubjects who refuse to participate, or demonstrate inability to give informed consentXx_NEWLINE_xXInability or unwillingness to provide informed consent to the studyXx_NEWLINE_xXUnwillingness or inability to comply with study proceduresXx_NEWLINE_xXInability to cooperate with the scansXx_NEWLINE_xXInability to lie flat for 60-90 minutesXx_NEWLINE_xXInability to lie still for the entire imaging time (approximately 30 minutes)Xx_NEWLINE_xXInability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)Xx_NEWLINE_xXInability to tolerate imaging procedures in the opinion of an investigator or treating physicianXx_NEWLINE_xXInability to tolerate imaging procedures in the opinion of the investigator or treating physicianXx_NEWLINE_xXInability to tolerate imaging procedures, in the opinion of an investigator or treating physicianXx_NEWLINE_xXInability to place an IV catheter or draw blood for any reasonXx_NEWLINE_xXInability to receive furosemide (Lasix) in the opinion of the treating investigatorXx_NEWLINE_xXDementia or other severe cognitive impairment causing inability to understand or consent to the procedure and studyXx_NEWLINE_xXPatients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the examXx_NEWLINE_xXInability to give written consentXx_NEWLINE_xXInability to adequately oxygenate the patient during the procedureXx_NEWLINE_xXInability to lie still for PET scanningXx_NEWLINE_xXInability to tolerate imaging procedures, in the opinion of an investigator or treating physicianXx_NEWLINE_xXInability to tolerate additional imaging time in the opinion of the investigator or treating physicianXx_NEWLINE_xXInability to tolerate 60 minutes of PET imagingXx_NEWLINE_xXInability to tolerate imaging procedures in the opinion of the investigator or treating physicianXx_NEWLINE_xXInability to tolerate imaging procedures in the opinion of an investigator or treating physicianXx_NEWLINE_xXInability or contraindication to undergo transcatheter arterial embolizationXx_NEWLINE_xXInability to lay flat for at least 2 consecutive hoursXx_NEWLINE_xXPatients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the examXx_NEWLINE_xXInability to lie still for the entire imaging timeXx_NEWLINE_xXInability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)Xx_NEWLINE_xXInability to comprehend or unwillingness to follow instructions for the study procedures required per protocolXx_NEWLINE_xXInability to lie in the PET/CT scanner for the time required for scanning, up to 1 hour and 15 minutes (min) at a time and possibly with arms raised above the head for lung imagingXx_NEWLINE_xXInability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.)Xx_NEWLINE_xXInability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)Xx_NEWLINE_xXRefusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)Xx_NEWLINE_xXInability to tolerate imaging procedures in the opinion of an investigator or treating\r\nphysicianXx_NEWLINE_xXPatients with inability to cooperate for an MRI exam due to claustrophobia or high levels of anxietyXx_NEWLINE_xXInability or unwillingness to undergo PET scanningXx_NEWLINE_xXInability to give informed consentXx_NEWLINE_xXDONOR: Inability to give informed consentXx_NEWLINE_xXInability to comply with the photosensitivity precautions associated with the studyXx_NEWLINE_xXClaustrophobia or inability to tolerate MRI examination (lay still for approximately 1 hour and hold breath intermittently)Xx_NEWLINE_xXInability to lie still for the duration of the scanning procedureXx_NEWLINE_xXInability to tolerate imaging procedures (e.g. claustrophobia, severe pain)Xx_NEWLINE_xXInability to exercise on a treadmill or stationary cycleXx_NEWLINE_xXRefusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)Xx_NEWLINE_xXSubjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcherXx_NEWLINE_xXSubjects who have cardiac or known circulatory impairment, and/or the inability to perspire (poor thermoregulatory function)Xx_NEWLINE_xXInability to lie in the scanner for 30 minutesXx_NEWLINE_xXInability or unwillingness to cooperate with requirements of this trialXx_NEWLINE_xXInability or unwillingness of research participant, parent, or legal guardian/representative to give written informed consentXx_NEWLINE_xXEXCLUSION CRITERIA FOR OPEN-ACCESS: Inability or unwillingness of research participant, parent, or legal guardian/representative to give written informed consentXx_NEWLINE_xXInability to understand and/or carry out instructionsXx_NEWLINE_xXInability or unwillingness to undergo the complete series of imaging sessions; inability or unwillingness to complete the one month follow-upXx_NEWLINE_xXInability to understand the risks and benefits of the studyXx_NEWLINE_xXPatient Volunteers: Inability to understand the risks and benefits of the studyXx_NEWLINE_xXPatient Volunteers/Contrast Enhancement Sub-group: Inability to understand the risks and benefits of the studyXx_NEWLINE_xXInability to perform informed consent due to any medical or psychiatric conditionXx_NEWLINE_xXAn inability to lie still for the testsXx_NEWLINE_xXUnwillingness or inability to give informed consentXx_NEWLINE_xXInability to tolerate MRI (e.g., inability to lie flat for > 1 hour)Xx_NEWLINE_xXInability to lie still for PET scanningXx_NEWLINE_xXInability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.)Xx_NEWLINE_xXInability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)Xx_NEWLINE_xXInability to lie comfortably on a bed inside the scanner for 60 minutes as assessed by physical examination and medical history (e.g. back pain, arthritis)Xx_NEWLINE_xXInability to lie still for PET scanningXx_NEWLINE_xXSubjects who refuse to participate, or demonstrate inability to give informed consentXx_NEWLINE_xXInability to cannulate the common bile ductXx_NEWLINE_xXRefusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)Xx_NEWLINE_xXInability to give informed consentXx_NEWLINE_xXInability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.)Xx_NEWLINE_xXInability to complete the needed investigational due to other reasons (severe claustrophobia, radiation phobia, etc.)Xx_NEWLINE_xXInability to lie still for the entire imaging timeXx_NEWLINE_xXInability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)Xx_NEWLINE_xXInability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (e.g. severe claustrophobia)Xx_NEWLINE_xXInability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.); although at Mission Bay Hospital pediatric patients may be sedated per clinical protocolXx_NEWLINE_xXInability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)Xx_NEWLINE_xXInability to give informed consentXx_NEWLINE_xXInability to tolerate imaging procedure (i.e., remain relatively still for multiple short durations of 3-4 minutes) over a total time of 20 minutesXx_NEWLINE_xXInability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.)Xx_NEWLINE_xXInability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)Xx_NEWLINE_xXInability to lie still for PET scanningXx_NEWLINE_xXInability to give informed consent or to comply with all study proceduresXx_NEWLINE_xXInability to lie still for the imaging studyXx_NEWLINE_xXContraindication for or inability to tolerate MRI examinationXx_NEWLINE_xXInability to lie still for the entire imaging timeXx_NEWLINE_xXInability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)Xx_NEWLINE_xXSubjects incapable of giving informed written consent, for the following reasons:\r\n* Inability to adhere to the experimental protocols for any reason\r\n* Inability to communicate with the research team\r\n* Mental disability, altered mental status, confusion, or psychiatric disorders\r\n* Prisoners or others susceptible to coercionXx_NEWLINE_xXPregnant women are excluded from participation due to inability to participate in required chemotherapy regimenXx_NEWLINE_xXinability to comply with the protocolXx_NEWLINE_xXInability to tolerate 18F-fluciclovine PET/CTXx_NEWLINE_xXInability to give informed consentXx_NEWLINE_xXInability to lie still for the entire imaging timeXx_NEWLINE_xXInability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)Xx_NEWLINE_xXInability to tolerate MRI including conditions such as claustrophobia or inability to lay flat for > 45 minutesXx_NEWLINE_xXInability to complete the needed investigational and standard-of-care imaging examinations due to other reasonsXx_NEWLINE_xXInability to comply with instructionsXx_NEWLINE_xXInability to tolerate scanning (e.g. - claustrophobia, severe pain)Xx_NEWLINE_xXInability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)Xx_NEWLINE_xXInability to give informed consent in personXx_NEWLINE_xXPhysical inability to undergo a scanning procedure (e.g., inability to lie flat for the required period of time – three sessions of roughly an hour each with ten minutes’ rest in between)Xx_NEWLINE_xXInability to lie still for imagingXx_NEWLINE_xXRegular use of thiazide diuretics (i.e., hydrochlorothiazide), which can lead to hypercalcemia, and unwillingness or inability to discontinue or switch to an alternative anti-hypertensive agentXx_NEWLINE_xXInability to undergo leukapheresisXx_NEWLINE_xXInability to give informed consent.Xx_NEWLINE_xXBIODISTRIBUTION COHORT: Inability to tolerate imaging procedures in the opinion of an investigator or treating physicianXx_NEWLINE_xXDYNAMIC COHORT: Inability to tolerate imaging procedures in the opinion of an investigator or treating physicianXx_NEWLINE_xXInability to participate in physical activity because of severe disability (e.g., severe arthritic conditions)Xx_NEWLINE_xXThe patient has an inability or unwillingness to abide by the study protocol or cooperate fully with the investigator or designee.Xx_NEWLINE_xXSubjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcherXx_NEWLINE_xXInability to abstain from taking anything by mouth for at least 6 hoursXx_NEWLINE_xXInability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol. Note the following pertains to patients enrolled in FranceXx_NEWLINE_xX